RGNT
Regentis Biomaterials Ltd.
There isn't enough reported data to score RGNT yet.
RGNT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RGNT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
RGNT PE Valuation
RGNT has no meaningful PE right now: it lost money over the past year.
RGNT Forward outlook
There aren't enough analyst estimates for RGNT to show an outlook.
RGNT Earnings Per Share
RGNT Quarterly Revenue
RGNT Free Cash Flow
RGNT Total Shares
RGNT Net Leverage
RGNT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RGNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.8 | Neutral |
| Stochastic | 6.8 | Oversold |
RGNT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
RGNT PE vs Healthcare Sector
RGNT has no meaningful PE right now: it lost money over the past year.
RGNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.50 | 17% below |
| 20 week MA | $1.98 | 37% below |
| 50 week MA | $3.30 | 62% below |
RGNT is in a downtrend: it's below all three of its weekly moving averages, and 62% below its 50-week average.
RGNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $7.49 | $6.93 | -7.5% |
| 2026 YTD | $6.93 | $1.25 | -82% |
RGNT has finished every year since 2025 lower, and it's down 82% so far in 2026.